IN8bio (INAB)

• Market cap: $18M
• 1 day: 3.49%
• 5 days: -17.07%
• 1 month: -22.61%
• 3 months: -20.84%
• 6 months: -72.96%
• Year to date: -81.15%
• 1 year: -82.23%
• 5 years: -97.51%
• 10 years: -97.51%
• Sector: Healthcare
• Industry: Biological Products, Except Diagnostic Substances

About: IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.

Employees: 18

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

17% more repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 6

0% more funds holding

Funds holding: 26 [Q2] → 26 (+0) [Q3]

0% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 6

1.25% less ownership

Funds ownership: 17.55% [Q2] → 16.3% (-1.25%) [Q3]

70% less capital invested

Capital invested by funds: $6.77M [Q2] → $2.04M (-$4.73M) [Q3]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $8 3,115% upside
• Avg. target: $8 3,115% upside
• High target: $8 3,115% upside

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Swayampakula Ramakanth 30% 1-year accuracy 52 / 173 met price target

3,115% upside $8

Buy Reiterated

26 Nov 2024